Leukemia, Myelogenous, Chronic, BCR-ABL Positive: all 982 studies
Page 7 of 10. Open to participants first (109), then studies with results posted, then the rest; newest registration first within each.
- CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell TransplantActive, not recruitingNCT02061800Phase 1/2
- Occupational Status and Hematological DiseaseCompletedNCT02057185
- Evaluating the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Chronic Myelogenous LeukemiaTerminatedNCT02047149Phase 1
- Patterns of ABL Mutation in Asian With Imatinib Resistant Chronic Myeloid Leukemia and Ph Positive Acute Lymphocytc Leuekmia Patients (AMICA)Status unknownNCT02034656
- Development of Immunological Assays for the Evaluation of Tumor Antigen Specific ImmunityCompletedNCT02016833
- Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single VaccinationStatus unknownNCT02007811Phase 1/2
- Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid LeukaemiaCompletedNCT02001818Phase 2
- Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological DiseasesTerminatedNCT01962636Not applicable
- Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular ResponseCompletedNCT01933906Phase 1
- OPTIM DASATINIB (Optimized Tyrosine Kinase Inhibitors Monotherapy)CompletedNCT01916785Phase 2
- Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-LeukemiaCompletedNCT01914484Phase 1/2
- Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In RemissionStatus unknownNCT01901666Phase 4
- Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS TrialStatus unknownNCT01887561Phase 2
- Combination of Dasatinib and Peg-Interferon Alpha 2b in First Line for Chronic Myeloid Leukemia in Chronic PhaseCompletedNCT01872442Phase 2
- Nilotinib Plus Pegylated Interferon-α2b in CMLTerminatedNCT01866553Phase 2
- TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy and Tolerability. The TIKlet StudyCompletedNCT01860456
- Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ CellsCompletedNCT01856283Phase 2
- Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell TransplantCompletedNCT01822509Phase 1
- Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid HemopathyCompletedNCT01819558Phase 1/2
- Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment IntoleranceCompletedNCT01819389Phase 3
- Pulmonary Vasculopathy Under Second-line Therapy of Chronic Myeloid LeukemiaCompletedNCT01805843
- De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid LeukaemiaCompletedNCT01804985Phase 2
- Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic PhaseStatus unknownNCT01802450Phase 2
- Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)CompletedNCT01774630Phase 2
- Interventional Study to Improve Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid LeukemiaCompletedNCT01768689Not applicable
- Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With DasatinibStatus unknownNCT01761890
- Chronic Myelod Leukemia Registry at Asan Medical CenterTerminatedNCT01761695
- Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood DisordersCompletedNCT01758042Not applicable
- A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute LeukemiaCompletedNCT01756118Phase 1
- Phase III Study of Compound Formula Realgar-Indigo Naturalis Plus Imatinib Versus Placebo Plus Imatinib in Adult CML-CP Patients With Ph+SuspendedNCT01755325Phase 3
- Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase InhibitorsStatus unknownNCT01752062
- A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I)CompletedNCT01751919Phase 1
- Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase InhibitorsTerminatedNCT01751425Phase 1
- Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD ProphylaxisTerminatedNCT01749111Phase 3
- Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the InvestigatorCompletedNCT01742299Phase 4
- Safety and Efficacy of Pegylated IFN-alpha 2B Added to Dasatinib in Newly Diagnosed Chronic Phase Myeloid LeukemiaCompletedNCT01725204Phase 2
- Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) PatientsCompletedNCT01702064Phase 1
- Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic PhaseCompletedNCT01699217
- Nilotinib-Chemotherapy in CML Myeloid BP or Bcr-abl(+) AMLStatus unknownNCT01690065Phase 2
- Study With Intravenous Busulfan And Fludarabine Myeloablative Conditioning Regimen For HLA Identical Sibling Donor HSCTCompletedNCT01683123
- An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer StudiesCompletedNCT01677780Phase 1
- Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous LeukemiaWithdrawnNCT01670084Phase 2
- Phase I Study of Milatuzumab for Graft Versus Host DiseaseTerminatedNCT01663766Phase 1
- Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic MalignanciesCompletedNCT01658319Phase 1
- TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER StudyCompletedNCT01657604Phase 3
- Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic MalignanciesWithdrawnNCT01652014Phase 2
- Imatinib Response in Patients With Chronic Myeloid Leukemia (CML) in Function of Abl PolymorphismsWithdrawnNCT01650467
- Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell TransplantationCompletedNCT01634217Phase 1
- Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop TrialStatus unknownNCT01627132Phase 2
- WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity StudyCompletedNCT01621724Phase 1/2
- NK Cells in Cord Blood TransplantationStatus unknownNCT01619761Phase 1
- Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid MalignanciesCompletedNCT01606579Phase 1/2
- Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase.WithdrawnNCT01605981Phase 4
- Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKICompletedNCT01602952Phase 1/2
- Trial of Haploidentical Stem Cell Transplantation for Haematological CancersCompletedNCT01597219Phase 2
- European Stop Tyrosine Kinase Inhibitor StudyCompletedNCT01596114Phase 3
- Expanded Access Program of PonatinibApproved for marketingNCT01592136
- Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell TransplantCompletedNCT01588015Phase 1
- Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML PatientsCompletedNCT01578213Phase 4
- Discontinuation Study of Imatinib in Adult CP CML Patients Who Have a Complete Molecular Response to ImatinibStatus unknownNCT01564836Not applicable
- Prospective Investigation of Dynamics of ABL Mutations in Imatinib Failed CML Patients Treated With NilotinibStatus unknownNCT01562847
- Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell TransplantWithdrawnNCT01558778Not applicable
- Compassionate Use PonatinibNo longer availableNCT01549548
- Nilotinib in PH+, BCR-, ABL+ CML PatientsCompletedNCT01535391Phase 3
- Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid MalignanciesCompletedNCT01523223Phase 1
- Improving Blood Stem Cell Collection and Transplant ProceduresCompletedNCT01517035Phase 1/2
- Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic LeukemiaStatus unknownNCT01513603Phase 2
- Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase PatientsCompletedNCT01511289Phase 3
- A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous LeukemiaStatus unknownNCT01503502Phase 2
- Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-MatchTerminatedNCT01500161Phase 2
- Administration of Donor T Cells With the Caspase-9 Suicide GeneActive, not recruitingNCT01494103Phase 1
- Telemonitoring Study - for Chronic Myeloid Leukemia (CML)TerminatedNCT01490983Not applicable
- Follow-up of Ph+ Chronic Myleoid Leukemia Patients in Complete Cytogenetic Response With Interferon Based TherapyCompletedNCT01490853
- Sirolimus/Tacrolimus Combination After HLA Matched Related Peripheral Blood Stem Cell TransplantsTerminatedNCT01488253Phase 2
- Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile NeutropeniaCompletedNCT01484015Phase 1
- Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With NilotinibCompletedNCT01475110
- Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia in JapanStatus unknownNCT01464411
- Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid LeukaemiaCompletedNCT01460693Phase 3
- Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)CompletedNCT01460498Phase 1
- Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior TherapyCompletedNCT01456676Phase 1
- Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic MalignancyWithdrawnNCT01452334Phase 1
- Pharmacogenomics Validation for Imatinib in Chronic Myeloid LeukemiaCompletedNCT01437202
- Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib MesylateTerminatedNCT01426334Phase 1
- Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic MalignanciesCompletedNCT01413568Phase 1/2
- Efficacy of Nilotinib Versus Imatinib in Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to ImatinibStatus unknownNCT01400074Phase 3
- Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML)TerminatedNCT01397734Phase 1
- Non-interventional Treatment Patterns Study in Chronic Phase Chronic Myelogenous Leukemia (CP-CML)CompletedNCT01394666
- Bioequivalence And Food Effect Study Of Bosutinib In Healthy SubjectsCompletedNCT01374139Phase 1
- Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 TrialCompletedNCT01368523Phase 4
- Unrelated Donor Stem Cell TransplantationCompletedNCT01364363Not applicable
- Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukaemia in Long Term After Stopping ImatinibCompletedNCT01343173Not applicable
- A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With DasatinibCompletedNCT01342679Phase 2
- Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous LeukemiaCompletedNCT01316250Not applicable
- TXA127 in Enhancement of Engraftment in Adult Double Cord Blood TransplantationTerminatedNCT01300611Phase 1
- Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for LeukemiaCompletedNCT01297543Phase 1/2
- Nilotinib + Pegylated Interferon Alpha 2a for Untreated Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT01294618Phase 2
- Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)CompletedNCT01279473Phase 1/2
- Nonmyeloablative Allogeneic TransplantCompletedNCT01272817Not applicable
- Study to Evaluate the Pharmacokinetic Characteristics of Luckyvec 400mg Tablet, in Healthy SubjectsCompletedNCT01270984Phase 1
- Patient Reported Outcomes in Chronic Myeloid LeukemiaCompletedNCT01252589